Targeting non-coding RNAs to overcome cancer therapy resistance
Abstract It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts, are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are widely appreciated as pervasive regulators of multiple...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2022-04-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-022-00975-3 |
| _version_ | 1818050422291562496 |
|---|---|
| author | BaoQing Chen Mihnea P. Dragomir Chen Yang Qiaoqiao Li David Horst George A. Calin |
| author_facet | BaoQing Chen Mihnea P. Dragomir Chen Yang Qiaoqiao Li David Horst George A. Calin |
| author_sort | BaoQing Chen |
| collection | DOAJ |
| description | Abstract It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts, are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are widely appreciated as pervasive regulators of multiple cancer hallmarks such as proliferation, apoptosis, invasion, metastasis, and genomic instability. Despite recent discoveries in cancer therapy, resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy continue to be a major setback. Recent studies have shown that ncRNAs also play a major role in resistance to different cancer therapies by rewiring essential signaling pathways. In this review, we present the intricate mechanisms through which dysregulated ncRNAs control resistance to the four major types of cancer therapies. We will focus on the current clinical implications of ncRNAs as biomarkers to predict treatment response (intrinsic resistance) and to detect resistance to therapy after the start of treatment (acquired resistance). Furthermore, we will present the potential of targeting ncRNA to overcome cancer treatment resistance, and we will discuss the challenges of ncRNA-targeted therapy—especially the development of delivery systems. |
| first_indexed | 2024-12-10T10:53:13Z |
| format | Article |
| id | doaj.art-f53841bc61ce490b838c6002f740738c |
| institution | Directory Open Access Journal |
| issn | 2059-3635 |
| language | English |
| last_indexed | 2024-12-10T10:53:13Z |
| publishDate | 2022-04-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Signal Transduction and Targeted Therapy |
| spelling | doaj.art-f53841bc61ce490b838c6002f740738c2022-12-22T01:51:57ZengNature Publishing GroupSignal Transduction and Targeted Therapy2059-36352022-04-017112010.1038/s41392-022-00975-3Targeting non-coding RNAs to overcome cancer therapy resistanceBaoQing Chen0Mihnea P. Dragomir1Chen Yang2Qiaoqiao Li3David Horst4George A. Calin5Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, GuangzhouInstitute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of HealthDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, GuangzhouDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, GuangzhouInstitute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of HealthDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer CenterAbstract It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts, are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are widely appreciated as pervasive regulators of multiple cancer hallmarks such as proliferation, apoptosis, invasion, metastasis, and genomic instability. Despite recent discoveries in cancer therapy, resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy continue to be a major setback. Recent studies have shown that ncRNAs also play a major role in resistance to different cancer therapies by rewiring essential signaling pathways. In this review, we present the intricate mechanisms through which dysregulated ncRNAs control resistance to the four major types of cancer therapies. We will focus on the current clinical implications of ncRNAs as biomarkers to predict treatment response (intrinsic resistance) and to detect resistance to therapy after the start of treatment (acquired resistance). Furthermore, we will present the potential of targeting ncRNA to overcome cancer treatment resistance, and we will discuss the challenges of ncRNA-targeted therapy—especially the development of delivery systems.https://doi.org/10.1038/s41392-022-00975-3 |
| spellingShingle | BaoQing Chen Mihnea P. Dragomir Chen Yang Qiaoqiao Li David Horst George A. Calin Targeting non-coding RNAs to overcome cancer therapy resistance Signal Transduction and Targeted Therapy |
| title | Targeting non-coding RNAs to overcome cancer therapy resistance |
| title_full | Targeting non-coding RNAs to overcome cancer therapy resistance |
| title_fullStr | Targeting non-coding RNAs to overcome cancer therapy resistance |
| title_full_unstemmed | Targeting non-coding RNAs to overcome cancer therapy resistance |
| title_short | Targeting non-coding RNAs to overcome cancer therapy resistance |
| title_sort | targeting non coding rnas to overcome cancer therapy resistance |
| url | https://doi.org/10.1038/s41392-022-00975-3 |
| work_keys_str_mv | AT baoqingchen targetingnoncodingrnastoovercomecancertherapyresistance AT mihneapdragomir targetingnoncodingrnastoovercomecancertherapyresistance AT chenyang targetingnoncodingrnastoovercomecancertherapyresistance AT qiaoqiaoli targetingnoncodingrnastoovercomecancertherapyresistance AT davidhorst targetingnoncodingrnastoovercomecancertherapyresistance AT georgeacalin targetingnoncodingrnastoovercomecancertherapyresistance |